Neonatal Lipid Supplement Market

How big is Neonatal Lipid Supplement Market in 2026?

Demand for neonatal lipid supplements is projected to expand at 7.8% CAGR between 2026 and 2036. Industry value grows from USD 80.0 million in 2025 to USD 86.2 million in 2026 and is projected to reach USD 182.8 million by 2036.

Neonatal lipid supplements are used where premature infants cannot receive required lipid energy from normal feeding volume. The global market was valued at USD 80.0 million in 2025 and is projected to grow from USD 86.2 million in 2026 to USD 182.8 million by 2036, at 7.8% CAGR. MCT emulsions accounted for 42.4% of demand in 2026, as measured dosing provides concentrated energy in a small feeding volume. The U.S. recorded 3,606,400 provisional births in 2025, including 10.41% preterm births and 2.69% early preterm births.[1] This provides a measurable infant base where feeding immaturity can require specialist nutrition. Johns Hopkins recommends parenteral nutrition for preterm neonates below 1,800 grams when close to full enteral feeding is not expected within three days.[2] In June 2026, Fresenius launched Pedismof with age-specific three-chamber bags for preterm neonates and children, which is expected to increase adoption of standardized products.[3] According to FMI, products supporting controlled dosing under hospital feeding protocols will witness higher clinical adoption.

Key Market Trends & Insights

• By lipid type, MCT emulsions led with 42.4% share in 2026, as concentrated energy and measured small-volume dosing supports neonatal feeding.
• Caloric density enhancement represented 41.7% of application demand in 2026, owing to the requirement of additional calories without proportional fluid intake.
• By product form, liquid emulsions held 55.7% share in 2026, and ready-to-use pediatric bags are reducing reconstitution and compounding work.
• NICUs accounted for 45.9% of end-user revenue in 2026, as lipid initiation, laboratory monitoring and dose advancement remains under specialist care.
• Hospital pharmacy generated 48.5% of sales-channel revenue in 2026, due to route checks, sterile handling, storage and institutional product control.

Regional Highlights

• Fastest-growing profiled country: South Korea, at 8.3% CAGR from 2026 to 2036.
• By country: The UK, at 7.4%, and the USA, at 7.1%, follow, while Japan records the lowest profiled CAGR at 6.1%.

Market Size & Forecast

Table 1: Market Size and Forecast for the Neonatal Lipid Supplement Market (USD million and percentage), 2025 to 2036

Metric	Value
2025 Market Size	USD 80.0 million
Estimated Market Size in 2026	USD 86.2 million
Projected Market Size by 2036	USD 182.8 million
CAGR, 2026 to 2036	7.8%
Added Revenue, 2026 to 2036	USD 96.6 million
Market Expansion Multiple	2.12 times

The addressable market remains smaller than total premature births, as neonatal lipid use is decided by weight, feeding maturity, route and monitoring. Children’s Hospital of Philadelphia supports a 2 g/kg/day starting infusion and a 3 g/kg/day goal, with triglyceride checks during dose advancement.[6] A 2025 study covered 207 preterm infants receiving at least seven days of total parenteral nutrition, including 103 infants receiving SMOFlipid and 104 receiving nutrition without lipid emulsion.[7] Another 2025 cohort included 139 infants born before 32 weeks or below 1,250 grams, and linked standardized parenteral nutrition with higher day-28 weight and fewer prolonged stays.[8] Thus, repeat demand is created through daily weight-based dosing, while feeding advancement limits the duration of product use.

Clinical Need and Addressable Demand

Table 2: Clinical Need and Addressable Demand for the Neonatal Lipid Supplement Market (births, patients, weight thresholds, dosing, and percentages), mixed reporting years from 2024 to 2026

Indicator	Data Point	Market Meaning	Source
U.S. births and preterm rate	3,606,400 births; 10.41% preterm in 2025	Supports a broad population requiring neonatal assessment, though not every preterm infant receives lipid supplementation.	[1]
U.S. early preterm rate	2.69% in 2025	Early preterm infants have greater feeding immaturity and specialist nutrition requirement.	[1]
South Korea high-risk registry	2,331 infants; more than 70 NICUs in 2024	Shows concentrated clinical access through a national specialist network.	[4]
Very-low-birthweight survival	90.0% at discharge in South Korea during 2024	Improving survival increases the group requiring growth monitoring and follow-up.	[4]
PN eligibility pathway	Preterm neonates below 1,800 g when full enteral feeds are not expected within 3 days	Defines a clinically narrower group than total preterm births.	[2]
Lipid dose pathway	2 g/kg/day starting dose; 3 g/kg/day goal	Weight-based daily dosing supports recurring monitored use during PN.	[6]
Clinical cohort scale	207 preterm infants receiving at least 7 days of TPN	Shows the treatment duration and monitored hospital use examined for mixed-oil emulsions.	[7]
Standardized PN cohort	139 infants below 32 weeks or 1,250 g	Links protocol-based nutrition with growth and hospital-outcome assessment.	[8]

Analyst Perspective

“I expect measured lipid products to receive higher use as hospitals reduce preparation work and standardize neonatal feeding plans. Products supporting controlled dosing from NICU initiation to pediatric follow-up will create the strongest expansion opportunity.”

- Anurag Sharma, Principal Consultant, Future Market Insights.

How is the neonatal lipid supplement market segmented?

Neonatal lipid supplement market is segmented by five primary categories and region: lipid type, application, product form, end user, sales channel, and region. In 2026, MCT emulsions are projected at 42.4%, caloric density enhancement at 41.7%, and liquid emulsions at 55.7%.

Neonatal lipid supplement market is segmented by lipid type, application, product form, end user, sales channel, and region.

By lipid type: MCT emulsions, LCT emulsions, MCT/LCT blends, and other lipid types.

By application: caloric density enhancement, chylothorax management, cholestasis-adapted feeding, and other applications.

By product form: liquid emulsions, powders, and oils.

By end user: NICUs, pediatric wards, homecare, and other end users.

By sales channel: hospital pharmacy, retail pharmacy, online, institutional tender, and other channels.

By region: North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Why do MCT emulsions retain a notable lipid type share?

MCT emulsions are projected to hold 42.4% of lipid type demand in 2026, supported by concentrated energy delivery.

Table 3: Lipid Type Share for the Neonatal Lipid Supplement Market (percentage share), 2026

Lipid Type	Share (2026)
MCT Emulsions	42.4%
Other Segments Combined	57.6%*
Total	100.0%

*Calculated as the balance remaining after deducting the leading segment's reported share from 100.0%.

Table 4: Lipid Type Leadership and Market Growth for the Neonatal Lipid Supplement Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	7.8%
Leading Segment	MCT Emulsions

MCT emulsions are concentrated fat sources utilizing medium-chain triglycerides which provides energy without adding the same feeding volume. These emulsions are used where fat absorption or tolerated feed volume remains limited. FMI research indicates that due to concentrated energy density, MCT products can be integrated into volume-restricted feeding regimens. However, the amount is controlled for maintaining essential fatty acid intake. Wider use of measured lipid modulars is anticipated to support the MCT emulsions segment during the forecast period.

• MCT emulsions account for 42.4% of lipid type revenue in 2026, as modular dosing separates energy adjustment from the total feed volume.
• In October 2025, Fresenius Kabi described SMOFlipid as a four-oil emulsion used for pediatric patients, including preterm neonates.[9]

What supports caloric density enhancement within the application category?

By application, caloric density enhancement is estimated to hold 41.7% in 2026, owing to volume-limited feeding needs.

Caloric density enhancement is used when premature infants receiving enteral nutrition require more energy but cannot tolerate higher feed volume. Respiratory support, fluid restriction and feeding immaturity can reduce the feed received by an infant. Addition of lipid modulars raises the calorie level, while protein and mineral requirement can be adjusted separately. Due to this, concentrated feeding plans are expected to drive the segment growth.

• Caloric density enhancement represents 41.7% of application revenue in 2026, as energy can rise without delivering proportional fluid volume.
• In 2025, the American Academy of Pediatrics reported that concentrated neonatal enteral regimens providing up to 24 to 30 kcal/oz support daily weight velocity in fluid-restricted preterm infants.[10]

How do liquid emulsions meet neonatal product form needs?

In 2026, liquid emulsions are expected to lead product form with 55.7% share, enabled by measured small-volume dosing.

Liquid emulsions are ready for measured use and does not require powder reconstitution before administration. This lowers the preparation steps for small neonatal doses and supports controlled handling in hospitals. However, enteral and intravenous products cannot be used as replacement for each other. Availability of ready-to-use pediatric parenteral formula options is anticipated to support the liquid emulsions segment growth.

• Liquid emulsions hold 55.7% of product form revenue in 2026, as hospitals prefer measured handling and lower preparation requirement.
• In May 2024, Baxter secured FDA approval for Clinolipid with an expanded pediatric indication, providing lipid injectable emulsion for preterm and term neonates.[11]

Why do NICUs remain central to neonatal lipid end use?

NICUs are set to command 45.9% of end user demand in 2026, underpinned by specialist monitoring and initiation.

NICUs provide the specialist monitoring required during clinical nutrition protocols and neonatal lipid use. Neonatologists, dietitians, pharmacists and nurses adjusts lipid delivery according to growth, laboratory values and feeding tolerance. South Korea has more than 70 participating NICUs and registers over 2,000 high-risk infants each year. Presence of this specialist network is expected to support the NICUs segment growth.

• NICUs account for 45.9% of end-user revenue in 2026, as product initiation and monitoring remains concentrated in specialist units.
• In March 2025, the CDC National Center for Health Statistics reported that U.S. NICU admission rates reached 92.5 per 1,000 live births, concentrating specialized nutrition and monitored lipid delivery within intensive care units.[12]

What keeps hospital pharmacy central to neonatal lipid sales?

Hospital pharmacy is forecast to represent 48.5% of sales channel revenue in 2026, driven by controlled institutional access.

Hospital pharmacy controls the availability and storage of neonatal lipid products within hospitals. Pharmacy teams also checks product route, formulation and compatibility with neonatal instruction before supply. Germany retained binding requirements for premature and term infant care from August 2026. Hospital-controlled specialized nutrition products are expected to support regular pharmacy demand over the forecast period.

• Hospital pharmacy represents 48.5% of sales-channel revenue in 2026, because neonatal product use follows institutional control.
• In 2025, the American Society for Parenteral and Enteral Nutrition issued updated clinical recommendations for lipid injectable emulsions, emphasizing hospital pharmacy oversight in sterile dispensing and shortage management.[13]

What are the drivers, restraints, and opportunities in the neonatal lipid supplement market?

In the neonatal lipid supplement market, concentrated energy is the key driver, narrow dosing tolerance is the key restraint, and care continuity is the key opportunity.

• Driver: Preterm growth needs and limited fluid volume increase demand for clinician-directed lipid energy.
• Restraint: Route-specific dosing, tolerance monitoring, and age evidence can slow hospital acceptance.
• Opportunity: Dose-standardized products can connect NICU initiation with pediatric follow-up and supervised homecare.

Restricted Volume Raises Energy Need

Premature infants may require higher energy than the amount provided through tolerated feeding volume. The World Health Organization reported that an estimated 13.4 million infants are born preterm annually, creating an extensive global population that requires specialized nutrition support when standard feeding volumes are restricted.[14] These infants can require controlled feeding when normal volume is not sufficient, supporting wider preterm birth prevention and management care protocols. As a result, use of concentrated neonatal lipid energy is expected to increase with specialist preterm care.

Monitoring Narrows Eligible Product Use

Neonatal lipid supplements requires route-specific dose, age evidence and regular tolerance monitoring. A 2025 clinical investigation in pediatric intensive care evaluated intravenous lipid emulsion administration and identified hypertriglyceridemia monitoring as essential to avoid tolerance complications during dose escalation.[15] Products without neonatal instruction, including broad cholestasis nutrition products, cannot be directly used as replacement for approved neonatal products. High evidence requirement and longer hospital approval may limiting the market growth.

Discharge Pathways Extend Supervised Demand

Better survival of premature infants is adding more infants requiring nutrition follow-up after intensive care. A 2025 clinical review in Seminars in Fetal and Neonatal Medicine emphasized post-discharge nutritional regimens to support continuous catch-up growth during outpatient transition.[16] Hospital feeding plans can continue through pediatric follow-up, children enteral nutrition, and supervised homecare. Availability of dose-standardized products is therefore expected to create opportunities after NICU discharge.

Which country CAGRs are profiled in the neonatal lipid supplement market?

Table 5: Country CAGR Comparison for the Neonatal Lipid Supplement Market (CAGR percentage), 2026 to 2036

Country	CAGR, 2026 to 2036
USA	7.1%
UK	7.4%
Germany	6.6%
Japan	6.1%
South Korea	8.3%

How do country-level CAGRs compare in the neonatal lipid supplement market?

Country demand conditions differ across neonatal networks, hospital qualification standards, and national birth trends. As noted by FMI, South Korea and the UK are projected to grow faster than Germany and Japan through 2036. The USA has a large premature infant population, but product review by individual hospitals can result in different adoption period.

• USA demand follows decentralized hospital protocols and a large preterm population, which supports regular assessment of concentrated neonatal nutrition.
• UK purchasing remains protocol-led through NHS neonatal and pharmacy pathways, and approved products can receive regular institutional use.
• Germany concentrates high-risk care in regulated perinatal centers, due to which product documentation remains important before hospital acceptance.
• Japan combines mature specialist care with a declining birth cohort, restricting volume growth while supporting measured neonatal use.
• South Korea connects national registry evidence with more than 70 NICUs, allowing common treatment practices to move through participating hospitals.

Full report country CAGRs cover: North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa.

Country-wise Analysis

• Adoption of neonatal lipid supplements in the USA is estimated to grow at 7.1% CAGR through 2036. The National Center for Health Statistics recorded 377,204 preterm births in the United States during 2024, creating an extensive inpatient base requiring specialized neonatal nutrition protocols.[17] Premature infants may require concentrated lipid energy and regulated medical food when normal feeding volume does not meet growth requirement. The country has a large number of hospital systems, but products are reviewed by local clinical and pharmacy teams. Large groups can adopt one feeding protocol across several sites. This hospital base and preterm population is anticipated to support demand in the USA.
• Demand for neonatal lipid supplements in the UK is forecast to rise at 7.4% CAGR through 2036. The Office for National Statistics reported annual birth trends in England and Wales,[5] confirming 585,396 live births for 2025, with birthweight and gestational age reporting informing specialized neonatal care allocation.[18] Birth information is also classified by gestational age and birthweight, which supports planning for higher-risk infants. Neonatal nutrition decisions are generally managed by specialist teams and hospital pharmacy under NHS care. Products having clear neonatal indication and compatibility with hospital practice can receive regular institutional use. Expansion of protocol-based neonatal care is anticipated to support the UK market growth.
• The neonatal lipid supplement market in Germany is projected to record 6.6% CAGR during the assessment period. The Federal Joint Committee changed its perinatal quality directive in June 2026, and the requirements became effective on August 11, 2026.[19] The directive defines hospital care levels and minimum requirements for premature and term infants. High-risk infants are treated in qualified centers where pharmacy and clinical teams follows documented procedures. This concentration supports regular institutional demand after product acceptance, but documentation can delay new product entry.
• Sales of neonatal lipid supplements in Japan are anticipated to grow at 6.1% CAGR between 2026 and 2036. The Ministry of Health, Labour and Welfare reported 671,236 births in 2025, decreasing by 2.2% from 2024.[20] Lower births limits the addition of new neonatal patients, although mature specialist perinatal care remains available. Neonatal lipid products requires accurate small-volume dosing and local medical information for use in qualified centers. Each center therefore represents a notable share of the addressable demand, while declining births may hamper volume-led growth.
• By 2036, neonatal lipid supplement demand in South Korea is projected to grow at 8.3% CAGR. The Korea Disease Control and Prevention Agency reported 2,331 high-risk infants in the 2024 registry, with discharge survival reaching 90.0% among very low birthweight infants and 91.6% overall.[4] More than 70 NICUs participates in the network and uses a common evidence base. Faster movement of neonatal practices between these hospitals is supporting adoption, while continued nutrition assessment after discharge can create additional demand.

Who are the notable companies in the neonatal lipid supplement market?

Baxter, Fresenius Kabi, Danone Nutricia, Abbott, Vitaflo / Nestle Health Science, Solace Nutrition, Mead Johnson / Reckitt, and Stepan are notable companies profiled in this market.

Neonatal lipid supplement market encompasses both parenteral lipid emulsions (intravenous administration) and enteral modular nutrition (oral/tube feeding). Fresenius Kabi and Baxter supply parenteral lipid emulsions for hospital intravenous use, while Danone Nutricia, Abbott and Mead Johnson reach buyers through enteral infant and medical nutrition channels. Vitaflo and Solace Nutrition offers specialist products, whereas Stepan supplies MCT ingredients to formulators. In the FMI report, competitive position is connected with pediatric clinical evidence and ease of integrating formulations into intensive care workflows. Hospitals compares neonatal indication, route, small-dose handling and regular availability before using a product. Documented pediatric use and technical information can therefore improve supplier acceptance during the forecast period.

• Parenteral lipid systems: Fresenius Kabi and Baxter supply hospital lipid-emulsion platforms.
• Clinical and infant nutrition access: Danone Nutricia, Abbott, and Mead Johnson / Reckitt reach neonatal decision-makers through established channels.
• Specialist modular and ingredient capability: Vitaflo, Solace Nutrition, and Stepan participate through modular or upstream lipid routes.

Competitive Benchmarking: Neonatal Lipid Supplement Market

Table 6: Competitive Benchmarking for the Neonatal Lipid Supplement Market (qualitative capability ratings), 2026

Company	Neonatal fit	Lipid depth	Institutional access	Geographic reach
Baxter	High	High	High	High
Fresenius Kabi	High	High	High	High
Danone Nutricia	Medium	High	High	High
Abbott	High	Medium	High	High
Vitaflo / Nestle Health Science	Medium	High	High	High
Solace Nutrition	Low	High	Medium	Medium
Mead Johnson / Reckitt	High	Medium	High	High
Stepan	Low	High	Low	High

High represents broad public evidence across the stated capability, Medium represents narrower evidence, and Low represents limited documented breadth. These ratings describe public company capability and do not indicate product quality, revenue share or company ranking.

Key Developments in the Neonatal Lipid Supplement Market

• In June 2026, Fresenius launched the Pedismof range in Europe. The ready-to-use three-chamber bags include age-specific formulations for preterm and term neonates.[3]
• In July 2025, Danone completed its majority acquisition of Kate Farms. The transaction expanded North American hospital and homecare channels for specialized nutrition.[21]
• In January 2025, Solace Nutrition reintroduced Encala through an alliance with Structured Lipid Nutrition. The medical food supports dietary fat absorption in fat-malabsorption disorders.[22]
• In October 2025, Fresenius Kabi reported more than 7 million SMOFlipid patients worldwide. The product is indicated for pediatric patients, including neonates.[9]

Key Players in the Neonatal Lipid Supplement Market

Parenteral lipid platforms

• Fresenius Kabi
• Baxter

Clinical nutrition access

• Danone Nutricia
• Abbott
• Mead Johnson / Reckitt

Specialist modular and ingredient providers

• Vitaflo / Nestle Health Science
• Solace Nutrition
• Stepan

Neonatal Lipid Supplement Market - Report Scope

Table 7: Report Scope for the Neonatal Lipid Supplement Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Lipid type; application; product form; end user; sales channel; region
Quantitative units	USD million
Market definition	First-sale revenue from standalone lipid-dominant neonatal nutrition products and dedicated lipid emulsions. Complete formulas and fortifiers are excluded.
Regions covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries profiled	USA; UK; Germany; Japan; South Korea
Forecast period	2026 to 2036
Proprietary data	Segment shares and forecast estimates are proprietary analytical estimates and are not government measurements of global market share.

Neonatal Lipid Supplement Market - Research Methodology

Table 8: Research Methodology for the Neonatal Lipid Supplement Market (research methods and approach), 2026 edition

Method	Approach
Primary Research	Primary research gathered input from manufacturers, distributors, end users, procurement teams and industry experts. Interviews covers product evaluation, purchasing decision, price, adoption barriers and approval requirement.
Desk Research	Desk research includes government statistics, regulatory publications, technical literature, company filings, product information and official announcements. Sources are reviewed according to date, market scope and geographic relevance.
Market Sizing and Forecasting	Market sizing combines baseline value, segment structure, price and volume indicators, adoption, company participation and country demand. Forecast considers neonatal protocols, survival, supply and hospital acceptance.
Data Validation	Market estimates are checked with public data, company activity, clinical indicators and primary findings. Adjacent products and overlapping revenue are excluded from the defined market.

Neonatal Lipid Supplement Market by Segments

Lipid type

• MCT emulsions
• LCT emulsions
• MCT/LCT blends
• Other lipid types

Application

• Caloric density enhancement
• Chylothorax management
• Cholestasis-adapted feeding
• Other applications

Product form

• Liquid emulsions
• Powders
• Oils

End user

• NICUs
• Pediatric wards
• Homecare
• Other end users

Sales channel

• Hospital pharmacy
• Retail pharmacy
• Online
• Institutional tender
• Other channels

Neonatal Lipid Supplement Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • Japan
  • South Korea
• South Asia and Pacific
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] Hamilton, B. E., Osterman, M. J. K., & Gregory, E. C. W. (2026, April). Births: Provisional Data for 2025. National Center for Health Statistics.
• [2] Johns Hopkins All Children’s Hospital. (2025, January). Parenteral nutrition for the preterm neonate clinical pathway.
• [3] Fresenius SE & Co. KGaA. (2026, June 8). Fresenius announces European launch of Pedismof range.
• [4] Korea Disease Control and Prevention Agency. (2026, January 8). Survival rate of very low birthweight infants reaches 90 percent.
• [5] Office for National Statistics. (2025, August 27). Births in England and Wales: 2024.
• [6] Children’s Hospital of Philadelphia. (2025). Preterm nutrition consensus: Part 2, parenteral nutrition.
• [7] Refaay, M. E. E., Yassine, O. G., Abu-Sheasha, G. A., & Zaki, A. (2025). Impact of SMOFlipid emulsion integration in total parenteral nutrition on inpatient outcomes and economic burden for preterm neonates. BMC Pediatrics, 25, 123.
• [8] Mahallei, M., Gorbani, L., Hoseini, M. B., Shaseb, E., Mehramuz, B., & Rezazadeh, K. (2025). The effect of implementing parenteral nutrition guideline on growth and clinical outcomes in preterm infants. BMC Pediatrics, 25, 399.
• [9] Fresenius Kabi. (2025, October 1). Parenteral nutrition portfolio.
• [10] American Academy of Pediatrics Committee on Fetus and Newborn. (2025). Enteral nutrition for the high-risk and preterm infant. Pediatrics, 155(2), e2024068912.
• [11] Baxter International Inc. (2024, May 13). Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication.
• [12] Martin, J. A., & Osterman, M. J. K. (2025, March). Increases in Neonatal Intensive Care Admissions in the United States, 2016-2023. NCHS Data Brief, No. 525. Centers for Disease Control and Prevention.
• [13] American Society for Parenteral and Enteral Nutrition. (2025). Parenteral Nutrition Product Considerations: Lipid Injectable Emulsions.
• [14] World Health Organization. (2024, March 14). Preterm birth: Key facts and global estimates.
• [15] Kim, S. H., & Park, E. J. (2025). Factors influencing hypertriglyceridemia and intravenous lipid emulsion dosage in very preterm infants. Journal of Perinatal Medicine, 53(4), 412-419.
• [16] Embleton, N. D., & Moltu, S. J. (2025). Post-discharge nutrition to optimize preterm infant short- and long-term outcomes. Seminars in Fetal and Neonatal Medicine, 30(2), 101637.
• [17] Centers for Disease Control and Prevention. (2025). Births: Final Data for 2024. National Vital Statistics System.
• [18] Office for National Statistics. (2026, May 27). Births in England and Wales: 2025.
• [19] Gemeinsamer Bundesausschuss. (2026, August 11). Quality assurance directive for premature and term infants.
• [20] Ministry of Health, Labour and Welfare, Japan. (2026). Vital Statistics of Japan 2025: Provisional annual totals.
• [21] Danone. (2025, July 1). Danone completes the acquisition of Kate Farms.
• [22] Solace Nutrition. (2025, January 15). Encala returns: Reintroduction of a medical food for fat malabsorption.

This bibliography is provided for reader reference. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the neonatal lipid supplement market during 2026?
• What value is projected for neonatal lipid supplements by 2036?
• Which lipid type holds a notable share in 2026?
• Which application accounts for a notable share during 2026?
• Which country has a notable neonatal lipid supplement growth outlook?
• Which companies are notable in the neonatal lipid supplement market?